信達生物(01801.HK)向Zieziula授出11.7萬股購股權及1.46萬股受限制股份
格隆匯6月1日丨信達生物(01801.HK)公吿,於2022年6月1日,根據首次公開發售後僱員持股計劃條款,公司向Zieziula先生授出117,045股購股權,行使價每股股份24.30港元。
此外,董事會宣佈,其已議決於授出日期根據2020年受限制股份計劃向Zieziula先生授出14,631股受限制股份,但須待接納及在股東大會上獲獨立股東批准,方可作實。
建議授出受限制股份構成Zieziula先生薪酬的一部分,並已獲公司薪酬委員會批准。鑑於Zieziula先生於加入集團前曾在多家大型製藥公司及生物技術公司成功領導藥物全球商業化,具有豐富經驗,故對製藥行業管道的全球佈局、評估及推廣具有深刻見解,建議授出受限制股份旨在吸引、鼓舞、激勵及獎勵Zieziula先生及鼓勵其努力提升公司及符合公司及股東整體利益的股份價值,向董事會提供其有關制訂公司策略及長期發展的獨立意見及判斷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.